Multi-layered graft for tissue engineering applications

Patent metadata

Field	Value
Publication number	US-12576192-B2
Application number	US-202318244351-A
Country	US
Kind code	B2
Filing date	Sep 11, 2023
Priority date	Jul 26, 2017
Publication date	Mar 17, 2026
Grant date	Mar 17, 2026

Abstract

A multi-layer device is provided that is useful in tissue regeneration, for example, for vascular regeneration, e.g., for use in treatment of a coronary vascular disease, such as for treatment of myocardial infarction. A method of making the device also is provided.

First claim

We claim:

1 . A multi-layer synthetic graft device comprising:
a first tubular, porous, biodegradable polymer matrix, the first tubular, porous, biodegradable polymer matrix formed by electrospinning and configured to prevent cellular migration therethrough; an ECM gel layer disposed circumferentially about the first porous, biodegradable polymer matrix; and a second tubular, porous, biodegradable polymer matrix disposed circumferentially about the ECM gel, the second tubular, porous, biodegradable polymer matrix formed by thermally induced phase separation and configured to permit cellular migration therethrough.

2 . The device of claim 1 , wherein a thickness of the first tubular, porous, biodegradable polymer matrix is at least 100 μm.

3 . The device of claim 2 , wherein a suture retention force of the device is more than 2N.

4 . The device of claim 1 , wherein the ECM gel is prepared from vascular tissue.

5 . The device of claim 1 , wherein the first tubular, porous, biodegradable polymer matrix, and/or the second tubular, porous, biodegradable polymer matrix comprises one or more of: poly(lactic acid) (PLA); poly(trimethylene carbonate) (PTMC); poly(caprolactone) (PCL); poly(glycolic acid) (PGA); poly(glycolide-co-trimethylenecarbonate) (PGTMC); poly(L-lactide-co-glycolide) (PLGA); polyethylene-glycol (PEG-) containing block copolymers; polyphosphazene; poly(ester urethane) urea (PEUU); poly(ether ester urethane) urea (PEEUU); poly(ester carbonate) urethane urea (PECUU); poly(carbonate) urethane urea (PCUU); a polyurethane; a polyester; a polymer comprising monomers derived from alpha-hydroxy acids such as: polylactide, poly(lactide-co-glycolide), poly(L-lactide-co-caprolactone), polyglycolic acid, poly(dl-lactide-co-glycolide), and/or poly(l-lactide-co-dl-lactide); a polymer comprising monomers derived from esters including polyhydroxybutyrate, polyhydroxyvalerate, polydioxanone, and/or polyglactin; a polymer comprising monomers derived from lactones; or a polymer comprising monomers derived from carbonates including polycarbonate, polyglyconate, poly(glycolide-co-trimethylene carbonate), or poly(glycolide-co-trimethylene carbonate-co-dioxanone).

6 . The device of claim 1 , wherein the first tubular, porous, biodegradable polymer matrix and the second tubular, porous, biodegradable polymer matrix comprise PCUU.

7 . The device of claim 1 , wherein:
the first tubular, porous, biodegradable polymer matrix has an inner diameter ranging from 1 mm to 2 mm; the device has a total thickness of from 200 μm to 1 mm; a thickness of the combined layers of the first tubular, porous, biodegradable polymer matrix plus the ECM gel ranges from 100 μm to 500 μm; or a thickness of the second tubular, porous, biodegradable polymer matrix plus the ECM gel ranges from 50 μm to 250 μm.

8 . The device of claim 1 , wherein one or both of the first tubular, porous, biodegradable polymer matrix and the second tubular, porous, biodegradable polymer matrix comprises an anti-thrombogenic polymer composition.

9 . The device of claim 1 , comprising:
a first tubular layer of a porous, biodegradable polymer matrix formed by electrospinning and configured to prevent cellular migration therethrough; a layer of vascular ECM gel disposed circumferentially about the first tubular layer; and a second tubular layer of a porous, biodegradable polymer matrix disposed circumferentially about the ECM gel, the second tubular layer formed from PEUU by thermally-induced phase separation, the second tubular layer configured to permit cellular migration therethrough, wherein a thickness of the first layer and the layer of vascular ECM gel ranges from 150 μm to 350 μm.

10 . A method of making a synthetic tubular graft device, comprising:
forming a first tubular, porous, biodegradable polymer matrix by electrospinning; depositing an ECM gel layer over the first tubular, porous, biodegradable polymer matrix to produce a tubular, multi-layer structure; and inserting the tubular, multi-layer structure into a second, tubular, porous, biodegradable polymer matrix formed by thermal induced phase separation, thereby producing a tubular graft device.

11 . The method of claim 10 , wherein the first tubular, porous, biodegradable polymer matrix is a dry-electrospun matrix.

12 . The method of claim 10 , wherein the ECM gel is prepared from vascular tissue.

13 . The method of claim 10 , wherein the first tubular, porous, biodegradable polymer matrix and/or the second tubular, porous, biodegradable polymer matrix comprises one or more of: poly(lactic acid) (PLA); poly(trimethylene carbonate) (PTMC); poly(caprolactone) (PCL); poly(glycolic acid) (PGA); poly(glycolide-co-trimethylenecarbonate) (PGTMC); poly(L-lactide-co-glycolide) (PLGA); polyethylene-glycol (PEG-) containing block copolymers; polyphosphazene; poly(ester urethane) urea (PEUU); poly(ether ester urethane) urea (PEEUU); poly(ester carbonate) urethane urea (PECUU); poly(carbonate) urethane urea (PCUU); a polyurethane; a polyester; a polymer comprising monomers derived from alpha-hydroxy acids such as: polylactide, poly(lactide-co-glycolide), poly(L-lactide-co-caprolactone), polyglycolic acid, poly(dl-lactide-co-glycolide), and/or poly(l-lactide-co-dl-lactide); a polymer comprising monomers derived from esters including polyhydroxybutyrate, polyhydroxyvalerate, polydioxanone, and/or polyglactin; a polymer comprising monomers derived from lactones; or a polymer comprising monomers derived from carbonates including polycarbonate, polyglyconate, poly(glycolide-co-trimethylene carbonate), or poly(glycolide-co-trimethylene carbonate-co-dioxanone).

14 . The method of claim 10 , wherein the first tubular, porous, biodegradable polymer matrix and the second tubular, porous, biodegradable polymer matrix comprise PCUU.

15 . The method of claim 10 , comprising:
dry electrospinning a PCUU onto a mandrel to form the first tubular, porous, biodegradable polymer matrix; placing the mandrel comprising the first tubular, porous, biodegradable polymer matrix within a cylindrical mold having an inside diameter greater than an outside diameter of the first tubular, porous, biodegradable polymer matrix; depositing an ECM pre-gel about the first tubular, porous, biodegradable polymer matrix; gelling the ECM pre-gel about the first tubular, porous, biodegradable polymer matrix; and inserting the ECM gel-coated first tubular, porous, biodegradable polymer matrix into the second tubular, porous, biodegradable polymer matrix, wherein the second tubular, porous, biodegradable polymer matrix comprises a PCUU matrix.

16 . The method of claim 10 , wherein:
the first tubular, porous, biodegradable polymer matrix has an inner diameter of from 1 mm to 2 mm; the device has a wall thickness of from 200 μm to 1 mm; a thickness of the combined layers of the first tubular, porous, biodegradable polymer matrix plus the ECM gel ranges from 100 μm to 500 μm; or a thickness of the second tubular, porous, biodegradable polymer matrix plus the ECM gel ranges from 50 μm to 250 μm.

17 . The method of claim 10 , wherein one or both of the first tubular, porous, biodegradable polymer matrix and the second tubular, porous, biodegradable polymer matrix comprises an anti-thrombogenic polymer composition.

18 . The method of claim 10 , wherein a thickness of the first tubular, porous, biodegradable polymer matrix is at least 100 μm.

19 . The method of claim 18 , wherein a suture retention force of the device is more than 2N.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education
• Ri Med Found

Inventors

• D'Amore Antonio
• Solazzo Matteo
• Wagner William R

Classifications

• A61L2430/40

  Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking · CPC title

• A61L2430/22

  for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus · CPC title

• A61L33/0005

  Use of materials characterised by their function or physical properties · CPC title

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61L31/148

  Materials at least partially resorbable by the body · CPC title